Monash IVF Knockback Sends Shares Lower
Monash IVF Group (ASX:MVF) shares slid nearly 6% to A$0.72 on Monday after the board rejected a revised A$0.90 per share takeover bid from a consortium led by Genesis Capital and Washington H. Soul Pattinson (ASX:SOL). This is the second rejection in five months, following the knockback of an A$0.80 offer in November 2025. Here is the puzzle: rejecting a higher bid would normally push shares up, yet the market is selling. So what is really going on?
Why the Board Says A$0.90 Still Undervalues Monash IVF
The board’s reasoning is simple. It argues A$0.90 sits at a “substantial discount to comparable IVF transactions” in Australia. The 2022 takeover of Virtus Health was struck at over 11x EBITDA. The earlier A$0.80 bid implied just 7.7x EBITDA on FY25 earnings, and A$0.90 still falls well short of that benchmark. In dollar terms, the rejected offer valued the whole company at roughly A$350 million.
The underlying numbers give the board some cover. FY25 revenue grew 6.7% to A$271.9 million, and underlying EBITDA rose 5.6% to A$66.3 million, showing the core business is still growing. The weak spot was underlying NPAT, which slipped 8.1% to A$27.4 million after damage from two embryo incidents disclosed in 2025. With the recently appointed CEO, Dr Victoria Atkinson, already at the helm since January, the board wants shareholders to back her turnaround plan rather than accept a discounted exit.
In our view, the Virtus comparison may no longer hold. The embryo incidents have significantly changed MVF’s risk profile, and the board may be anchored to pre-crisis valuations that the market has already moved past.
Why the Market Is Selling Instead of Celebrating
The 6% drop to A$0.72, now well below the A$0.90 offer, tells us what investors really believe: another bid is unlikely. The consortium has said A$0.90 is its “highest amount” unless a competing offer emerges. That reads as a walk-away line, not a negotiation opener.
A few more signals matter. The consortium already owns 19.6% of Monash IVF and has not been lifting that stake aggressively. The offer deadline is today, 21 April, leaving almost no time for a sweetened bid. Soul Patts is a patient investor but has shown no sign of escalating.
Without a takeover bid supporting the price, the standalone case has to carry the stock. That case faces real challenges: reputational damage from the embryo incidents, the A$56 million class action already settled in 2024, no FY25 final dividend, and pressure on patient volumes. Fair value without a bid likely sits closer to A$0.60 to A$0.70 until a recovery becomes visible.
The Investor’s Takeaway
Three scenarios are worth considering. A sweetened consortium bid near A$0.95 to A$1.00 is possible but looks unlikely given the walk-away language. A standalone turnaround under Dr Atkinson is credible over time, but proof points are likely 12 to 18 months away. Most likely in the near term, the share price drifts back towards pre-bid levels around A$0.60.
For existing holders, this rejection removes the near-term catalyst, so patience is required. For new buyers, waiting until after the 21 April deadline may offer a better entry point. The board is playing a confident hand, but the market is pricing in scepticism. From here, execution on the standalone plan matters far more than takeover speculation.
